Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New research sheds light on HIV among transgender men and women
For pregnant women with HIV, dolutegravir-based regimens are apparently safest.
HIV advocates discuss how lessons from pandemic vaccine development can help fight COVID-19.
People living with HIV are learning how to cope with a new pandemic.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
A new study found that 44% of Medicaid enrollees with HIV who stopped antiretroviral treatment did not restart therapy within 18 months.
HIV itself doesn’t raise the risk of getting the new virus, but some HIV-positive people are prone to severe illness.
Experts recommend having at least a 30-day supply.
Amid talk of “ending HIV,” we must also focus on those with the virus, says Anthony S. Fauci, MD.
Pregnant women with HIV often don’t receive treatment per guidelines, according to a study of more than 1,800 HIV-positive pregnant women.
ViiV applies for FDA approval of HIV drug fostemsavir
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
April/May 2020 Survey
The retailer offers services such as routine checkups, eye and dental exams, and therapy and may expand nationwide.
Gilead’s HIV capsid inhibitor might need dosing only every six months
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.